FOI 26-2048 – Import Permit Records For MK-677 & Cjc–1295

Written by Claude Haiku 4.5 from the extracted text on 27 Feb 2026. It can miss or misread redacted and scanned pages. Check the source before relying on it.

This FOI release discloses import permit records for two research peptides: MK-677 (ibutamoren) and CJC-1295 (sermorelin analogue). The documents show multiple import authorizations for CJC-1295 spanning February to July 2025, with one authorization issued under section 47G of the Therapeutic Goods Act (TGA). The records indicate repeated import approvals across a five-month period, though specific authorization numbers are partially redacted. These substances are investigational compounds used in research contexts; neither is approved for therapeutic use in Australia. The release does not include clinical efficacy data, safety assessments, or justification for the import authorizations.